Disclaimer: IPO details, GMP, subscription figures, and other related information are for informational purposes only and may not always be accurate or up to date. Please verify the latest details from official sources before investing.
Incorporated in June 2022, Himalaya Nutravedics India Limited is a Hyderabad-based Ayurvedic and nutraceutical manufacturing company engaged in the formulation, manufacturing, and marketing of Ayurvedic and nutraceutical products.
Its product range includes Softgel Capsules, Tablets, Medicated Oils, Liquid Orals, Hardgel Capsules, and Protein Powders across therapeutic categories such as digestive health, immunity, metabolic health, and pain management.
The company markets its branded products through healthcare practitioners and also undertakes third-party contract manufacturing. It has expanded its presence across 17 states and one union territory in India.
Its manufacturing facility is located in Hyderabad, Telangana, and holds the following certifications:
As of April 30, 2026, the company had 80 employees.
| Category | Shares Offered | Shares Applied | Subscription Times (x) |
|---|---|---|---|
| QIB (Ex Anchor) | 4,74,000 (26.49%) | 0 | 0.00 |
| NII | 4,82,400 (26.96%) | 1,75,200 | 0.36 |
| bNII (> ₹10L) | 2,37,600 (13.28%) | 1,11,600 | 0.47 |
| sNII (< ₹10L) | 1,18,800 (6.64%) | 63,600 | 0.54 |
| Retail | 8,32,800 (46.55%) | 5,54,400 | 0.67 |
| Total | 17,89,200 (100.00%) | 7,29,600 | 0.41 |
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Profit* | Last Updated |
|---|---|---|---|---|---|
| 17-09-2026 | ₹106 | ₹0 | ₹106 ( 0.00% ) | ₹0.00 | 17-Sep-2026 10:30 AM |
A quick overview of the key Financial Performance of Himalaya Nutravedics India Limited.
*All values are in Rs. Cr
Revenue increased by 105%, Profit after Tax (PAT) increased by 231%, Total Assets increased by 126% between FY2025 and FY2026.
| Period Ended | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 14.43 | 21.00 | 43.07 |
| Assets | 6.09 | 10.82 | 24.42 |
| Total Income | 14.43 | 21.00 | 43.12 |
| Profit After Tax | 0.43 | 2.23 | 7.39 |
| EBITDA | 0.94 | 2.99 | 8.10 |
| Net Worth | 1.34 | 6.75 | 16.38 |
| Reserves & Surplus | 0.53 | 2.76 | 10.07 |
| Total Borrowings | 3.24 | 1.76 | 5.13 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Investors (IND) (Min) | 2 | 2,400 | ₹ 2,54,400 |
| Individual Investors (IND) (Max) | 2 | 2,400 | ₹ 2,54,400 |
| S-HNI (Min) | 3 | 3,600 | ₹ 3,81,600 |
| S-HNI (Max) | 7 | 8,400 | ₹ 8,90,400 |
| B-HNI (Min) | 8 | 9,600 | ₹ 10,17,600 |
| KPI | Latest |
|---|---|
| ROE (%) | 63.87 |
| ROCE (%) | 36.41 |
| Debt / Equity | 0.31 |
| RoNW (%) | 45.12 |
| PAT Margin (%) | 17.16 |
| EBITDA Margin (%) | 18.82 |
|
Pre IPO
Post IPO
|
|
| EPS (₹) |
12.05
-
|
| P/E (x) |
-
-
|
| Promoter Holding (%) |
95.14
-
|
